Human immunodeficiency virus-associated progressive multifocal leukoencephalopathy: apparent response to 3'-azido-3'-deoxythymidine.
We present the case of a 26-year-old human immunodeficiency virus-seropositive man who developed progressive multifocal leukoencephalopathy as the initial manifestation of AIDS. He appears to have responded dramatically to therapy with 3'-azido-3'-deoxythymidine (AZT). His neurologic status deteriorated shortly after an AZT dose reduction. He has stabilized since resuming his previous AZT dose. Although it remains unclear whether AZT is useful in the treatment of JC virus infection, we think that all AIDS patients with progressive multifocal leukoencephalopathy should be offered treatment with AZT, especially in light of recent reports describing a possible potentiation of human immunodeficiency virus infection of the central nervous system in this setting.
Conway
B
B
Department of Medicine, University of Manitoba, Winnipeg, Canada.
Halliday
W C
WC
Brunham
R C
RC
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000188:drug therapy; D000328:Adult; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007968:Leukoencephalopathy, Progressive Multifocal / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008854:Microscopy, Electron; D009836:Oligodendroglia / Q000382:microbiology / Q000648:ultrastructure; D027383:Papillomaviridae / Q000648:ultrastructure; D027382:Polyomaviridae; D015215:Zidovudine / Q000627:therapeutic use*
D015215:Zidovudine